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Abstract
Background: Epidemiologic studies have provided new insights into the association between psoriasis and cardiovascular
diseases. Previous population studies have examined hypertension frequency in psoriasis patients. However, the
relationship between severity of hypertension and psoriasis has not been characterized.
Objective: We sought to investigate whether patients with psoriasis have more difficult-to-manage hypertension compared
to non-psoriatic hypertensive patients.
Approach: We performed a case-control study using the University of California Davis electronic medical records. The cases
were defined as patients diagnosed with both psoriasis and hypertension, and controls were defined as patients with
hypertension and without psoriasis. In this identified population, 835 cases were matched on age, sex, and body mass index
(BMI) to 2418 control patients.
Key Results: Treatment with multiple anti-hypertensives was significantly associated with the presence of psoriasis using
univariate (p,0.0001) and multivariable analysis, after adjusting for diabetes, hyperlipidemia, and race (p,0.0001).
Compared to hypertensive patients without psoriasis, psoriasis patients with hypertension were 5 times more likely to be on
a monotherapy antihypertensive regimen (95% CI 3.607.05), 9.5 times more likely to be on dual antihypertensive therapy
(95% CI 6.68–13.65), 16.5 times more likely to be on triple antihypertensive regimen (95% CI 11.01–24.84), and 19.9 times
more likely to be on quadruple therapy or centrally-acting agent (95% CI 10.58–37.33) in multivariable analysis after
adjusting for traditional cardiac risk factors.
Conclusions: Psoriasis patients appear to have more difficult-to-control hypertension compared to non-psoriatic,
hypertensive patients.
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Introduction
An expanding number of epidemiologic and immunology
studies have provided new insight into the association between
psoriasis and cardiovascular diseases [1–9]. The initial link
between psoriasis and coronary artery disease was suggested in
the 1970s [10]. Since then, multiple population-based studies have
suggested an association between these two diseases [7,11–13].
Results from a large population-based study showed an increased
relative risk of myocardial infarction (MI) especially in young
patients with severe psoriasis [1,14,15]. Psoriasis appears to be an
independent risk factor for MI, even after controlling for
traditional cardiac risk factors [4,16,17]. Additional population-
based studies have supported a relationship between psoriasis and
cerebrovascular and peripheral vascular diseases [2,18].
Researchers have long suggested that vascular abnormalities
might be present in patients with psoriasis [19]. Since the 1920s,
histopathologists have observed the presence of abnormally dilated
and tortuous capillaries in the dermal papillae and upper one-third
of the dermis in psoriasis lesions [19]. The advent of electron
microscopy enabled further characterization of these capillaries.
These thin-walled vessels contained erythrocytes, displayed
prominent gaps between endothelial cells, and lacked pericytes
or surrounding smooth muscle cells [20]. Moreover, dilation of
these abnormal capillaries was observed prior to keratinocyte
hyperplasia in the early development of psoriasis lesions. Notably,
the convoluted capillaries remained apparent in the upper dermis
for many months even after cutaneous lesions had completely
resolved [21,22].
Previous large population studies have examined the relation-
ship between psoriasis and hypertension and have focused on the
frequency of hypertension occurrence in psoriasis patients
compared to non-psoriasis patients [3,23–25]. However, to our
knowledge, hypertension severity (as measured by complexity of
anti-hypertensive regimen) in psoriatic patients compared to non-
psoriatic, hypertensive patients has not been described.
The primary aim of the study is to elucidate the relationship
between the presence of psoriasis and severity of hypertension, as
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patient. Specifically, we sought to investigate whether patients with
psoriasis have more severe hypertension or more difficult-to-
manage hypertension compared to non-psoriatic hypertensive
patients.
Methods
Ethics Statement: This retrospective study was approved by the
Institutional Review Board at University of California Davis
(UCD). The Institutional Review Board at UCD approved a
waiver of informed consent for this study.
In this case-control study, we defined ‘‘cases’’ as patients
diagnosed with both psoriasis and hypertension and ‘‘controls’’ as
those with hypertension and without psoriasis.
We searched UCD Health System EMR database from January
1, 2004 to July 5 2009 to identify our study cohort. We initially
identified 1044 patients who had ICD-9 codes for both psoriasis
and hypertension. From this initial cohort, we performed manual
chart review, abstracting medical record individually to ensure
that these patients fulfilled the following three criteria: (1) the
diagnosis of psoriasis was given by a board-certified dermatologist,
(2) the diagnosis of hypertension was made by the primary care
physician, a cardiologist, or a nephrologist, and (3) the initial
diagnosis of psoriasis was made either before or within 10 years
after the diagnosis of hypertension. Of the 1044 patients identified
as potential cases through EMR, we excluded 209 patients who
did not meet the case definition. We included the remaining 835
patients as cases for the study—those having both psoriasis and
hypertension. These cases were frequency-matched in a 1:3 ratio
to 2418 controls (non-psoriatic, hypertensive patients) on age, sex,
and BMI. Inclusion in the control group required that hyperten-
sion was diagnosed by a primary care physician, cardiologist, or
nephrologist.
The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC 7) defines severity of hypertension based on the
number and classes of antihypertensive agents [26]. Based on the
JNC 7 criteria, we defined hypertension severity based on a
patient’s medication regimen: 0=controlled with lifestyle modifi-
cations, 1= monotherapy (excluding centrally acting agents),
2=dual therapy (excluding centrally acting agents), 3=triple
therapy (excluding centrally acting agents), 4= quadruple therapy
and/or centrally acting agent.
We used anti-hypertension regimen as a measure for hyperten-
sion severity rather than discrete blood pressure measures because
blood pressure measurements alone while on anti-hypertensive
Table 1. Demographic and clinical characteristics of patients
with psoriasis and hypertension (cases) and those with
hypertension without psoriasis (controls).
Variable
Psoriasis &
Hypertension
(N=835)
Hypertension
(N=2418) P-value
N% N %
Sex
Female 390 47% 1130 47% 0.99
{
Male 445 53% 1288 53%
Age
Mean (6SD) 61.5613.1 yr 61.7612.8 yr 0.70
*
BMI
Mean (6SD) 31.066.7 30.766.2 0.28
Race
White 319 38% 1120 46% 0.0058
{
Black 22 2.6% 165 6.8%
Asian 14 1.7% 80 3.3%
American Indian 4 0.5% 7 0.29%
Other 143 17% 540 22%
Unspecified 333 40% 506 20.9%
Smoking
Percentages are followed by number of cases (in parentheses). For race,
smoking status, and alcohol use, the analysis includes only patients with
complete data on these parameters.
{Chi-square test was used to determine significance.
{Fisher’s exact test was used to determine significance.
*Student’s t-test was used to determine significance.
doi:10.1371/journal.pone.0018227.t001
Table 2. Univariate analysis examining relationship between
hypertension severity and presence of psoriasis.
Variable Cases Controls
Crude
OR 95% CI
P-
value
N% N %
Sex
Female 390 47% 1130 47% – – –
Male 445 53% 1288 53% 1.00 0.86-1.17 0.99
Race
White 319 64% 1120 59% – – –
Black 22 4% 165 9% 0.47 0.30–0.74 0.0013
Asian 14 3% 80 4% 0.61 0.34–1.10 0.10
American
Indian
4 0.80% 7 0.37% 2.01 0.58–6.90 0.27
Other 143 28% 540 28% 0.93 0.74–1.16 0.52
Smoking
Never 382 47% 1093 52% – – –
Prior
Smoking
310 39% 745 36% 1.59 1.10–1.58 0.0025
Active
Smoking
113 14% 260 12% 1.38 1.07–1.77 0.01
Alcohol Use
No 308 41% 925 45% – – –
Yes 441 59% 1119 55% 1.18 0.10–1.40 0.05
Type II Diabetes Mellitus
No 381 46% 1181 49% – – –
Yes 454 54% 1237 51% 1.14 0.97–1.33 0.11
Hypertension
Lifestyle
Modification
113 14% 1248 54% – – –
Monotherapy 299 36% 728 30% 4.54 3.59–5.74 ,0.001
Dual Therapy 239 29% 301 12% 8.77 6.78–11.34 ,0.001
Triple Therapy 148 18% 116 4.80 12.09 10.33–19.21,0.001
Quadruple or
Central Acting
Therapy
36 4.30% 25 1% 15.90 9.22–27.44 ,0.001
doi:10.1371/journal.pone.0018227.t002
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hypertension severity. We consulted with two board-certified
University of California cardiologists to confirm that the use of
anti-hypertensive regimen to define hypertension severity was
applied adequately and accurately in our study. We also collected
data on demographic and traditional cardiac risk factors in our
study patients, including race, alcohol consumption, smoking
status, and the presence of diabetes mellitus or hyperlipidemia.
Univariate and multivariate logistic regression analyses were
performed. Factors that were significant on univariate analyses
(p,0.05) were included in the multivariate logistic regression
model. We also forced diabetes mellitus status into the multivariate
model due to its clinical relevance. All statistical analyses were
performed using SAS software, version 9.1 (SAS Institute). Two-
tailed tests were used for all statistical analyses.
Results
In this case-control study, the demographic and clinical factors
for the cases (psoriatic, hypertensive patients) and controls (non-
psoriatic, hypertension patients) are summarized in Table 1. Our
study groups had a slight male predominance (53%), mean age of
62, and body mass index of approximately 31.
Our univariate analysis showed that the severity of hyperten-
sion, as defined in by the number of anti-hypertensives, was
significantly associated with the presence of psoriasis (p,0.0001)
(Table 2), and this relationship remains significant after adjusting
for diabetes, hyperlipidemia, and race (p,0.0001) using a
multivariable conditional logistic regression model (Table 3).
Compared to hypertensive patients without psoriasis, psoriasis
patients with hypertension were 5 times more likely by
multivariate analysis to be on monotherapy antihypertensive
regimen (95% CI 3.60–7.05), 9.5 times more likely to be on dual
antihypertensive therapy (95% CI 6.68–13.65), 16.5 times more
likely to be on triple antihypertensive regimen (95% CI 11.01–
24.84), and 19.9 times more likely to be on quadruple therapy or
centrally-acting agent (95% CI 10.58–37.33), after adjusting for
diabetes, hyperlipidemia, smoking status, and race. These results
suggest a significant correlation between the treatment-refractory
hypertension and presence of psoriasis that is independent of other
known cardiovascular risk factors.
Discussion
The precise pathophysiologic mechanisms that underlie psori-
asis and hypertension are unknown. Researchers proposed that
adipose tissue in psoriasis patients serves as a major source of
angiotensinogen, which is subsequently converted to angiotensin II
[27]. Angiotensin II not only promotes salt retention by kidneys; it
also stimulates T-cell proliferation [28,29]. Angiotensin II also
appears to promote inflammation and the development of
atherosclerosis [30]. The association between psoriasis and
hypertension may also be attributed to the increased oxidative
stress in psoriasis patients [31]. Greater levels of reactive oxygen
species can damage endothelium-dependent vasodilation.
Some researchers have suggested that increased visceral adipose
tissue in psoriasis patients may contribute to hypertension
development. Increased visceral adipose tissue may be associated
with accumulation of perivascular fat, which can serve as a
reservoir for activated effector T cells that promote dysfunction in
both hypertension and psoriasis [1]. However, these findings do
not entirely explain the persistent, significant association between
psoriasis and hypertension after adjustments for BMI.
Other investigators suggest that endothelin-1 may play an
important role in the development of hypertension among
psoriasis patients. Endothelin-1 is a protein that constricts blood
vessels and increase blood pressure, and it is produced by several
different cell types including keratinocytes. While the level of
endothelin-1 is usually regulated through various mechanisms,
their expression appears to be altered in psoriasis patients [32].
Compared to individuals without psoriasis, the level of endothelin-
1 appears to be increased in lesional skin and the serum of psoriasis
patients. Furthermore, endothelin-1 level appears to correlate with
psoriasis disease severity [32]. Increased endothelin-1 levels are
thought to exert a greater vasoconstrictive effect on the blood
vessels, which contributes to the development of hypertension.
Previous population studies comparing psoriasis patients with the
generalpopulation have shown a modest increase in the relative risk
of developing hypertension (Table 4) [3,23,25,33]. Specifically, in a
prospective study among U.S. female nurses, Qureshi et al. found
that women with psoriasis experienced an increased risk for
developing hypertension (RR 1.17; 95% CI 1.06–1.30) [3]. In a
case-control study using a health-maintenance organization data-
base, investigators found modestly increased odds of having
hypertension among psoriasis patients (OR1.37, 95% CI: 1.29–
1.46) [23]. Most previous population studies have relied solely on
ICD-9 diagnostic codes to identify patients with psoriasis. However,
due to potential misclassification errors by providers or coders, not
all ICD-9-based diagnoses in the EMR or claims databases reflect
actual diagnoses of medical conditions, including psoriasis or
Table 3. Multivariate analysis examining relationship
between hypertension severity and presence of psoriasis
adjusting for diabetes mellitus, smoking, hyperlipidemia, and
race.
Variable Adjusted OR 95% CI P-value
Race
White – – –
Black 0.36 0.21–0.60 ,.001
Asian 0.66 0.34–1.25 0.20
American Indian 0.87 0.17–4.45 0.86
Other 1.03 0.80–1.32 0.83
Smoking
Never – – –
Prior Smoking 1216 0.95–1.55 0.11
Active Smoking 1.43 1.01–2.02 0.04
Type II Diabetes Mellitus
No – – –
Yes 1.07 0.83–1.37 0.62
Hyperlipidemia
No – – –
Yes 1.15 0.92–1.45 0.22
Hypertension
Lifestyle Modification – – –
Monotherapy 5.04 3.60–7.05 ,.001
Dual Therapy 9.55 6.68–13.65 ,.001
Triple Therapy 16.54 11.01–24.84 ,.001
Quadruple or Central Acting
Therapy
19.87 10.58–37.33 ,.001
Controls are age, sex, and BMI–matched.
doi:10.1371/journal.pone.0018227.t003
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individual physician notes to ascertain whether patients had
physician-diagnosed hypertension or psoriasis.
In this study, we sought to address whether psoriasis patients
have more difficult-to-control hypertension compared to hyper-
tensive patients without psoriasis. By defining cases as patients with
both psoriasis and hypertension and controls as patients with
hypertension alone, we ascertained that psoriasis patients were
more likely to require more anti-hypertensive medications
compared to those without psoriasis on both univariate and
multivariate analyses after adjusting for potential confounders.
These findings suggest that patients with psoriasis tend to have
required a greater number of anti-hypertensive classes prescribed
in these patients.
The findings of this study need to be interpreted in the context
of the study design. In this case-control study, the medical records
for the cases and the controls have been individually evaluated to
ensure that they represent true cases or controls. This method of
defining the cases and controls, though time-consuming, allowed
for more accurate identification of the comparison groups. While
this research methodology does not completely eliminate misclas-
sification errors, it greatly reduces the likelihood of misclassifica-
tion of cases or controls, a problem frequently encountered when
using ICD-9 codes alone in population studies. Despite our best
efforts to minimize misclassification errors, it is still possible that a
patient with potentially severe hypertension was not on multiple
anti-hypertensive medications due to not obtaining regular
medical care. Although the current medical literature remains
inconclusive at best regarding whether certain anti-hypertensive
medications exacerbate psoriasis, it is nevertheless important to
consider this possibility in a small number of patients. While we
considered assessing psoriasis severity, such assessment is ham-
pered by the lack of consistent PASI or body surface area
recordings. Furthermore, in comparison to hypertension that
follows a more predictive, progressive course, the clinical course
for psoriasis as measured by medications is much more variable
over several years. Therefore, the fluctuating nature of psoriasis
disease severity makes it potentially problematic to select one data
point to define the overall disease severity in a patient.
Our findings contribute to the current literature by elucidating
the relationship between psoriasis and hypertension. While previous
studies have shown modestly increased odds of having hypertension
among psoriasis patients, our study findings suggest that psoriasis
patients who have hypertension are more likely to have more
difficult-to-control hypertension and require a greater number of
anti-hypertensive medications than non-psoriatic, hypertensive
patients. These novel findings will contribute to our understanding
of the epidemiologic associations between these two conditions and
provide impetus for in-depth translational and basic investigations
that elucidate shared mechanisms for this epidemiologic observa-
tion. Furthermore, the results of this study may benefit physicians
who regularly treat hypertensive patients and alert them to the
Table 4. Studies of prevalence of hypertension among psoriasis patients.
Author and Journal Study Design Number of Psoriasis Patients Prevalence of Hypertension P-value
Armstrong, et al. 2010 (Current study) Case-Control 835 See details in text See details in text
Al Matari, et al. 2010
Japanese Dermatological Association
Case-Control -computerized
patient records
Mild-Moderate - 1661 OR=3.597
(95% CI 3.015–4.29)
,0.001
Severe - 129 OR=5.17
(95% CI 3.53–7.55)
Altobelli, et al. 2009
European Journal of Dermatology
Survey - questionnaires Total - 1376 Frequency of associated HTN
=12.9%
,0.001
Smokers (.15 cigarettes per day) OR=1.37
(95% CI 1.01–2.03)
Drinkers (.2 glasses/day of wine) OR=2.11
(95% CI 1.31–3.40)
Neimann, et al. 2009
Journal of the American
Academy of Dermatology
Cross-Sectional Study - UK
General Practice Research
Database
Mild – 127,706 OR=1.16
(95% CI 1.14–1.18)
95% CI
Severe – 3,854 OR=1.25
(95% CI 1.13–1.39)
Qureshi, et al. 2009
Archives of Dermatology
Cohort - women aged 27–44 in
1991, completed follow-up
questionnaire in 2005
78,061 out of the 116671 from the
1991 cohort responded in 2005
Age Adjusted RR=1.32
(95% CI 1.19–1.45)
Multivariate RR=1.17
(95% CI 1.06–1.30)
95% CI
Cohen, et al. 2010
Acta Derm Venereol
Case-Control – Clalit Health
Services Database
12,502 OR=1.37
(95% CI 1.29–1.46)
,0.001
Augustine, et al. 2010
ActaDerm Venerol
Case-Control – Health Insurance
Data in Germany using ICD-10
codes
33,981 OR=1.73
(95% CI 1.71–1.76)
N/D
Wu, et al. 2008
Journal of Drugs in Dermatology
Case Control - National
Health and Wellness Survey
1127 1.49
(95% CI 1.23–1.80)
,0.01
Kaye, Li, and Jick 2008
British Journal of Dermatology
Cohort – General Practice
Research Database
44,164 HR=1.09
(95% CI 1.05–1.14)
,0.001
Sommer, et al. 2006
Arch Dermatol Res
Case-Control 581 OR 3.27
(95% CI 2.41–4.43)
,0.001
doi:10.1371/journal.pone.0018227.t004
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hypertensive regimen to achieve adequate blood pressure control,
compared to other hypertensive patients.
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